SMAD4 alterations have been implicated in EMT progression and poor outcomes in metastatic CRC [27], while other TGF-beta pathway genes—including BMP7, TGFBR2, and ACVR1B—have been linked to CRC pathogenesis and prognosis [21,28,29]. This evidence concerns the gene SMAD4 and colorectal carcinoma.